Premium
P1‐277: SPECT IMAGING FOR AMYLOID PLAQUES WITH A NOVEL RADIOIODINATED LIGAND IN AN ALZHEIMER'S DISEASE MODEL
Author(s) -
Ji Bin,
Chen Chun Jen,
Bandou Kazunori,
Ashino Hiroki,
Shima Keiji,
Uchida Keisuke,
Fujimoto Ousuke,
Kitamura Chiemi,
Nakahara Yuto,
Shiraishi Hideaki,
Matsushima Satoshi,
Ono Maiko,
Zhang MingRong,
Tokunaga Masaki,
Minamihisamatsu Takeharu,
Fujinaga Masayuki,
Suhara Tetsuya,
Higuchi Makoto,
Yamada Kazutaka
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.517
Subject(s) - in vivo , metabolite , chemistry , positron emission tomography , spect imaging , pittsburgh compound b , imaging agent , ex vivo , preclinical imaging , ligand (biochemistry) , single photon emission computed tomography , in vitro , nuclear medicine , alzheimer's disease , pathology , medicine , biochemistry , receptor , biology , disease , microbiology and biotechnology
of AD was performed. All animal experiments were carried out under the approval of the relevant Institutional Animal Review Committee of Ege University, (Number: 2010-155) Izmir, Turkey. Results: Higher uptakes on hippocampus were observed at Ab 1-42 injected side in animal model of AD when compared with the control and na€ive groups. Saturated studies with Bioquin-7-carboxylic acid compound showed that 99mTc labeled Bioquin-HMPAO compound has specificity on amyloid plaques (Figure 1). Conclusions: Consequences of the whole experimental studies, it is proposed that the radiolabeled compound (99m Tc-Bioquin-HMPAO) might be improved and used as a novel brain amyloid plaque specific agent promising early diagnosis potential of AD.